OncoMatch/Clinical Trials/NCT06224387
CTS2190 Phase I /II Clinical Study in Patients
Is NCT06224387 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CTS2190 capsules for solid tumors.
Treatment: CTS2190 capsules — This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Required: Stage III, IV
locally advanced or metastatic solid tumors at screening who cannot be treated surgically
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
have failed standard treatment (PD during treatment or after the last treatment) recommended by the current clinical diagnosis and treatment standards or guidelines, or cannot tolerate standard treatment, or refuse standard treatment and/or currently have no effective treatment available
Cannot have received: radiotherapy for the target lesion
Treatment with radiotherapy for the target lesion within 4 weeks before the first administration of the investigational drug
Cannot have received: anti-tumor drugs/treatments (including but not limited to chemotherapy, targeted therapy, immunotherapy)
accepted any anti-tumor drugs/ treatments (including but not limited to chemotherapy, targeted therapy, immunotherapy) within 5 half-lives before the first administration of the investigational drug, whichever is longer
Cannot have received: herbal therapies with anti-tumor indications
patients who have received herbal therapies with anti-tumor indications within 1 week before the first administration
Cannot have received: other unlisted clinical investigational drugs or treatments
received other unlisted clinical investigational drugs or treatments within 4 weeks (or 5 drug half-lives, whichever is longer) before the first administration
Lab requirements
Blood counts
platelet ≥ lower limit of normal, ANC ≥ 1.5 × 10^9/L, hemoglobin ≥ 100 g/dL
Kidney function
blood creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
Liver function
TBIL ≤ 1.5 × ULN (exceptions for isolated bilirubin >1.5 × ULN if direct bilirubin <35% or Gilbert syndrome), ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN (with liver mets: ALT/AST ≤ 5 × ULN)
Cardiac function
QTcF ≤ 450 ms (male) or ≤ 470 ms (female)
good organ function at screening, including: Liver function: total bilirubin (TBIL) ≤ 1.5 × ULN ... ALT ≤ 2.5 × ULN ... AST ≤ 2.5 × ULN (for patients with liver metastases ... ALT ≤5 × ULN, AST ≤ 5 × ULN); Renal function: blood creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min ... Hematology: platelet ≥ the lower limit of the laboratory normal range, and absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, and hemoglobin ≥ 100 g/dL; Cardiac function: QTcF ≤ 450 ms (male) or ≤ 470 ms (female)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify